Bruker Acquires mNGS Disqver Platform to Expand Infection Detection Portfolio
BRKR has more than doubled off its 52-week low of $28.53.
Summary
Bruker acquires the metagenomic mNGS Disqver platform for detecting pathogenic microorganisms in blood, expanding its infection detection portfolio. The deal adds a next-generation sequencing-based diagnostic tool to Bruker's life sciences offerings. No financial terms were disclosed, but the acquisition aligns with Bruker's strategy to strengthen its position in clinical microbiology. This follows a challenging Q1 where net income dropped 79.9% due to restructuring costs and asset impairments. The move could signal a pivot toward higher-growth diagnostic markets.
At the time of this announcement, BRKR was trading at $58.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $28.53 to $64.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.